Skip to main content

Stem Cell Treatment May Become Option to Treat Nonhealing Bone Fractures

Stem Cell Treatment May Become Option to Treat Non healing Bone Fractures


Stem cell therapy enriched with a bone-regenerating hormone, insulin-like growth factor-I (IGF-I), can help mend broken bones in fractures that are not healing normally, a new animal study finds.
The results are being presented at The Endocrine Society's 93rd Annual Meeting in Boston.
A deficiency of fracture healing is a common problem affecting an estimated 600,000 people annually in North America, according to the principal investigator, Anna Spagnoli, MD, associate professor of pediatrics and biomedical engineering at the University of North Carolina at Chapel Hill.
"This problem is even more serious," Spagnoli said, "in children with osteogenesis imperfecta, or brittle bone disease, and in elderly adults with osteoporosis, because their fragile bones can easily and repeatedly break, and bone graft surgical treatment is often not successful or feasible"
Fractures that do not heal within the normal timeframe are called non-union fractures. Using an animal model of a non-union fracture, a "knockout" mouse that lacks the ability to heal broken bones, Spagnoli and her colleagues studied the effects of transplanting adult stem cells enriched with IGF-I. They took mesenchymal stem cells (adult stem cells from the bone marrow) of mice and engineered the cells to express IGF-1. Then they transplanted the treated cells into knockout mice with a fracture of the tibia, the long bone of the leg.
Using computed tomography (CT) scanning, the researchers showed that the treated mice had better fracture healing than did control mice either left untreated or treated only with stem cells. They found that the stem cells enriched with IGF-I became bone cells and helped the cells in the broken bones to repair the fracture, speeding the healing. Compared with controls left to heal on their own, treated mice had more bone bridging the fracture gap, and that new bone was three to four times stronger, according to Spagnoli.
"More excitingly, we found that stem cells empowered with IGF-I restored the formation of new bone in a mouse lacking the ability to repair broken bones. This is the first evidence that stem cell therapy can address a deficiency of fracture repair," she said.
This success in an animal model of fracture non-union, Spagnoli said, "is a crucial step toward developing a stem cell-based treatment for patients with fracture non-unions."
"We envision a clinical use of combined mesenchymal stem cells and IGF-1 similar to the approach employed in bone marrow transplant, in which stem cell therapy is combined with growth factors to restore blood cells," she said. "I think this treatment will be feasible to start testing in patients in a few years."
IGF-I is approved for treatment of children with a deficiency of this hormone, causing growth failure.
The National Institutes of Health supported this study through a NIDDK-NIH R01 grant.

Comments

Popular posts from this blog

Artificial pancreas ... an option

Coming Soon: 'Artificial Pancreas' Options for Diabetes Miriam E Tucker June 20, 2016   NEW ORLEANS — Nearly closed-loop systems (also referred to as an "artificial pancreas") for improving glycemic control and minimizing hypoglycemia in type 1 diabetes are advancing rapidly, including iterations that deliver insulin alone, insulin with glucagon, or glucagon alone. Findings for several of the products in development demonstrating improvements in glycemic control and reductions in hypoglycemia were presented here at the  American Diabetes Association (ADA) 2016 Scientific Sessions . "Some people may do well on insulin only, while others may need glucagon," Vincent Crabtree, PhD, director of the artificial pancreas program at JDRF, in New York, told  Medscape Medical News , adding, "JDRF would like people to have choice, and we'd like all to be covered [by payers]." The insulin-only hybrid closed-loop 670G system (Medtronic MiniMed) is the...

Erythropoietin as a Retinal Angiogenic Factor in Proliferative Diabetic Retinopathy

Although vascular endothelial growth factor (VEGF) is a primary mediator of retinal angiogenesis, VEGF inhibition alone is insufficient to prevent retinal neovascularization. Hence, it is postulated that there are other potent ischemia-induced angiogenic factors. Erythropoietin possesses angiogenic activity, but its potential role in ocular angiogenesis is not established. METHODS We measured both erythropoietin and VEGF levels in the vitreous fluid of 144 patients with the use of radioimmunoassay and enzyme-linked immunosorbent assay. Vitreous proliferative potential was measured according to the growth of retinal endothelial cells in vitro and with soluble erythropoietin receptor. In addition, a murine model of ischemia-induced retinal neovascularization was used to evaluate erythropoietin expression and regulation in vivo. RESULTS The median vitreous erythropoietin level in 73 patients with proliferative diabetic retinopathy was significantly higher than that in 71 patients with...

Do you know that ??

Dear Readers, do you know about risk factors of Lung cancer ? If you are residing in a city where polution is a great problem, like air pollution, then you be attacked by lung cancer. Also if you are a regular smoker then you are in great risk. Researches shows that only inhaling toxic smokes are not important. If you are containing " Genes " that causes lung cancer then you are in great risks. So, it is proved clinicaly that if you dont have a lung cancer gene then you may not attacked by lung cancer though you are a smoker or anything like this. But, the problem is we dont know that whether we have the gene responsible for lung cancer or not. So, it will better to quit smoking if you are a smoker. Also, clinicaly doctors get those poatients who have alredy developed a cancer after exposing to the risk factors for several years. So, if a person quits smoking even after 15years he will get rid from lung cancer. But, he must in a great risk.